# Progress Note 06 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Friedrich Nietzsche (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI019-SYN-TD
- Date: 1881-09-15
- Fictional facility: St. Posthumous Health Center
- Fictional author: Konrad Ellison-Mbatha, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Eight-week review of migraine prevention after the withdrawal. **S**

## History of present illness

Mr. Nietzsche returns eight weeks after starting galcanezumab and five weeks after the last butalbital tablet. His diary shows 7 headache days in the past four weeks, 4 with migraine features, and no attack lasting more than a day. He used acute medicine on 5 days: sumatriptan on 3, with relief within two hours in 2, and naproxen on 2. He has taken no combination tablets. The injections cause only brief redness, and his constipation is unchanged. The floaters in his right eye have nearly gone, with no new flashes. He sleeps about six hours after five CBT-I sessions. His mood is good. His HIV, hepatitis C and hepatitis B tests from the preventive visit were negative, and he was told by phone. He is writing for several hours on most days and walking as before. **S**

| Element | Detail |
|---|---|
| Headache days | 7 in the past four weeks, 4 with migraine features (from about 20 and 12 before treatment) |
| Acute medicine | 5 days: sumatriptan on 3, naproxen on 2 |
| Disability | MIDAS 31 (grade IV), from 74; HIT-6 58, from 68 |
| Mood | PHQ-9 4; GAD-7 3 |
| Sleep | About six hours |
| Screening results | HIV, hepatitis C and hepatitis B negative |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Eyes | Negative | Floaters nearly gone; no flashes, shadow or distortion on the Amsler grid |
| Gastrointestinal | Negative | No nausea between attacks; constipation unchanged |
| Neurological | Positive | Seven headache days in four weeks; no new features |
| Psychiatric | Negative | Mood good; PHQ-9 4 |

4 systems reviewed. **S**

## Current medications

- Naproxen 500 mg oral tablet, one tablet with food at the start of a migraine attack, may repeat once after 12 hours; no more than two days a week **S**
- Metoclopramide 10 mg oral tablet, one tablet with the acute medicine when a migraine attack brings nausea or vomiting; no more than two days a week **S**
- Galcanezumab 120 mg/mL auto-injector, 240 mg (two injections) under the skin as a first loading dose, then 120 mg once a month, for chronic migraine prevention **S**
- Sumatriptan 100 mg oral tablet, one tablet early in a migraine attack, may repeat once after 2 hours; no more than two days a week and no more than eight days a month **S**

## Allergies

- No known allergy **S**

## Objective

BP 112/72 mmHg; pulse 62 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 67 kg; BMI 22.1 kg/m². All vital signs are synthetic.

MIDAS 1, work days missed: 6 d; MIDAS 2, work days at half productivity or less: 10 d; MIDAS 3, household work days missed: 3 d; MIDAS 4, household days at half productivity or less: 5 d; MIDAS 5, family, social or leisure days missed: 7 d; PHQ-9: 4; GAD-7: 3. All results are synthetic.

## Change since baseline

- MIDAS 1, work days missed: 14 d at baseline, 6 d at this visit **S**
- MIDAS 2, work days at half productivity or less: 22 d at baseline, 10 d at this visit **S**
- MIDAS 3, household work days missed: 8 d at baseline, 3 d at this visit **S**
- MIDAS 4, household days at half productivity or less: 12 d at baseline, 5 d at this visit **S**
- MIDAS 5, family, social or leisure days missed: 18 d at baseline, 7 d at this visit **S**
- PHQ-9: 7 at baseline, 4 at this visit **S**
- GAD-7: 6 at baseline, 3 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 112/72, pulse 62 |
| Eyes | Repeat dilated examination of the right eye: the vitreous detachment is complete, with no retinal break or detachment; macula unchanged |
| Neurological | Normal |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Chronic migraine without aura on galcanezumab** (G43.709). A good early response: headache days down from about 20 to 7 and migraine days from about 12 to 4 in four weeks, so he no longer has headache on 15 or more days a month. The MIDAS of 31 still counts the weeks before treatment and the withdrawal weeks in its three-month recall. Efficacy will be judged formally at three months. **S**
   - Third galcanezumab injection, 120 mg, today.
   - Three-month review in four weeks, before he leaves for the winter; plan to continue for at least six to twelve months.
   - OnabotulinumtoxinA as the next option if the response fades.
2. **Medication overuse headache** (G44.40). Resolved: no overuse for five weeks and headache days well below 15 a month. **S**
   - Keep acute medicine to no more than eight days a month.
3. **Posterior vitreous detachment, right eye** (H43.811). Complete detachment without a break; symptoms resolved. **S**
   - Yearly dilated examination; same-day eye care for new warning symptoms.
4. **Chronic insomnia** (G47.00). Sleep lengthening with CBT-I. **S**
   - Finish the CBT-I course.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Red-flag screen (SNNOOP10): systemic signs, neurological signs, sudden onset, onset after 50, change in pattern, positional or Valsalva features, papilledema, progressive course | Every visit | Completed today | No red flags |
| Survey | Headache diary: headache days, migraine days, attack features, triggers | Every visit | Completed today | 7 headache days and 4 migraine days in four weeks |
| Medication safety | Acute-medicine days (overuse limits: combination analgesics, triptans fewer than 10 days a month, simple analgesics fewer than 15) | Every visit | Completed today | Acute medicine on 5 days: sumatriptan on 3, naproxen on 2; no combination tablets |
| Medication safety | Galcanezumab tolerability: injection sites, constipation, blood pressure, hypersensitivity | Before starting and at each injection visit | Completed today | Brief redness only; constipation unchanged; blood pressure 112/72; third dose given today |
| Examination | Preventive efficacy (at least 50% fewer monthly migraine days; headache days below 15 a month) | At three months on treatment | Due | Early response at eight weeks (migraine days 12 to 4); formal judgment at the three-month review |
| Survey | Disability (MIDAS, recorded as its five items, and HIT-6) | At baseline and after two to three months of treatment | Completed today | MIDAS items 6, 10, 3, 5 and 7 days, total 31 (grade IV), from 74; the recall includes the weeks before treatment; HIT-6 58, from 68 |
| Survey | Mood (PHQ-9) and anxiety (GAD-7), with direct questions about hopelessness and self-harm | At baseline and at two to three months; questions at every visit | Completed today | PHQ-9 4, item 9 scored 0; GAD-7 3 |
| Examination | Dilated re-examination after an acute posterior vitreous detachment | Within six weeks of the detachment, sooner with new symptoms | Completed today | Six weeks after the detachment: complete, with no retinal break or detachment |
| Examination | Comprehensive eye examination: refraction, pupils, pressure, dilated fundus examination, macular OCT | At diagnosis, then yearly for pathologic myopia, and urgently for new flashes, floaters or a shadow | Up to date | Comprehensive examination eight weeks ago; next in one year |
| Self-management | Sleep: hours, sleep diary, insomnia severity; no sedative sleeping tablets | Every visit | Completed today | About six hours after five CBT-I sessions; no sleeping tablets |
| Self-management | Reading, writing and walking plan | Every visit | Completed today | Writing several hours a day with breaks; daily walks continue |

## Goal progress

- A two-week headache diary and the tests that allow a firm diagnosis. Outcome by 1881-07-21: Diary of 14 days kept; ICHD-3 criteria for chronic migraine and medication overuse headache met; MRI normal; syphilis serology nonreactive. **S**
- Stop the butalbital combination safely. Outcome by 1881-08-18: Three-week taper completed a week before the four-week review; no withdrawal seizure or delirium; withdrawal headache settled within ten days. **S**
- Fewer than 15 headache days a month, and at least half as many migraine days, within three months of starting prevention. In progress; target 1881-10-13. **S**
- Acute medicine on no more than eight days a month after withdrawal. Outcome by 1881-09-15: Acute medicine on 5 days in the past four weeks; no butalbital or combination product since the taper. **S**
- Clear vision in the left eye for reading and protection of the right eye. Outcome by 1881-08-18: Contact lenses fitted; left eye 20/20 and right eye 20/100 corrected; knows the warning signs of retinal detachment. **S**
- Six and a half hours of sleep on most nights without sleeping tablets. In progress; target 1881-10-13. **S**

## Guideline basis

- Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (2018), International Headache Society (Cephalalgia 2018;38(1):1-211)
- The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice (2021), American Headache Society (Headache 2021;61(7):1021-1039)
- Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update (2024), American Headache Society (Headache 2024;64(4):333-341)
- European Academy of Neurology guideline on the management of medication-overuse headache (2020), European Academy of Neurology (European Journal of Neurology 2020;27(7):1102-1116)
- European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update (2022), European Headache Federation (Journal of Headache and Pain 2022;23(1):67)
- Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation (2018), European Headache Federation (Journal of Headache and Pain 2018;19(1):91)
- Choosing wisely in headache medicine: the American Headache Society's list of five things physicians and patients should question (2013), American Headache Society (Headache 2013;53(10):1651-1659)
- Refractive Errors Preferred Practice Pattern (2023), American Academy of Ophthalmology (Ophthalmology 2023;130(3):P1-P60)
- Posterior Vitreous Detachment, Retinal Breaks, and Lattice Degeneration Preferred Practice Pattern (2025), American Academy of Ophthalmology (Ophthalmology 2025;132(4):P163-P196)
- Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline (2021), American Academy of Sleep Medicine (Journal of Clinical Sleep Medicine 2021;17(2):255-262)
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge

## Follow-up

- Three-month review in four weeks, before he leaves for the winter, with the fourth injection and a plan for care by the sea. Second hepatitis B vaccine dose in two weeks. **S**

